EUVIMEDEUVIMED entdecken
Crossref

MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK/c-Jun and p38 MAPK signaling pathway activation

Peng Gu, Wentao Ding, Wenting Zhu, Ling Shen, Lei Zhang, Wei Wang, Ruitao Wang, Wenhao Wang, Yanhao Wang, Bin Yan, Xing Sun

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.113191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Peng Gu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 201620, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Biomarkers, Tumor, MicroRNAs, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Breast cancer has the highest incidence rate and causes the most fatalities among all female cancers worldwide. Triple-negative breast cancer (TNBC) is known for its strong invasiveness and higher rates of recurrence. In this research, we aimed to identify MIR4435-2HG as a promising long non-coding RNA (lncRNA) biomarker and therapeutic target for TNBC. METHODS: Utilizing clinicopathological information and transcriptome data from The Cancer Genome Atlas (TCGA) database, we assessed the clinical relevance of MIR4435-2HG in breast cancer through univariate and multivariate COX regression, receiver operating characteristic (ROC) analysis, as well as Kaplan-Meier survival analysis. To investigate the biological role of MIR4435-2HG in TNBC, we conducted gene set enrichment analysis (GSEA), as well as Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Additionally, we constructed and validated a nomogram to predict disease-free survival (DFS). Both the R package "pRRophetic" and the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm were employed to forecast the sensitivity to different therapeutics between the high- and low-MIR4435-2HG groups. We employed single-cell RNA sequencing analysis and tumor microenvironment infiltration analysis to investigate the potential involvement of MIR4435-2HG in the TNBC tumor microenvironment. Cellular biological behaviors were assessed utilizing CCK-8, transwell assays, and wound-healing assays. Furthermore, we performed RNA-seq, qRT-PCR, and western blotting analyses to elucidate and confirm the specific mechanisms underlying the role of MIR4435-2HG in TNBC. RESULTS: In our study, we have identified MIR4435-2HG as a significant diagnostic and prognostic factor for TNBC. We observed that MIR4435-2HG is widely expressed and might have a significant impact on the reshaping of the TNBC tumor microenvironment. Patients with TNBC in the high-MIR4435-2HG group may show reduced sensitivity to cisplatin, doxorubicin, and gemcitabine and have an increased propensity for immune escape. Knockdown of MIR4435-2HG inhibits cancer-associated fibroblasts (CAFs) activation. Notably, MIR4435-2HG predominantly enhances the migratory and invasive capabilities of TNBC cells through the epithelial-mesenchymal transition (EMT) process. Mechanistically, we validated that MIR4435-2HG activates the JNK/c-Jun and p38 non-classical MAPK signaling pathway in TNBC cells. CONCLUSIONS: Our findings highlight the significant potential of MIR4435-2HG as a highly promising biomarker for TNBC. Targeting MIR4435-2HG could represent an appealing therapeutic approach for TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsBiomarkers, TumorMicroRNAsEpithelial-Mesenchymal TransitionCancer-Associated FibroblastsHumansFemalePrognosisCell Line, TumorNeoplasm InvasivenessRNA, Long NoncodingGene Expression Regulation, Neoplasticp38 Mitogen-Activated Protein KinasesTumor MicroenvironmentMAP Kinase Signaling SystemMiddle AgedCell Movement

Stichwörter der Autor:innen

Biological MarkersCancer-Associated FibroblastsMAP Kinase Signaling SystemMIR4435-2HGTriple Negative Breast NeoplasmsTumor Microenvironment

Substanzen

Biomarkers, TumorMicroRNAsRNA, Long Noncodingp38 Mitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 201620, China.
  • Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 201620, China; Clinical Medical School, Shanghai General Hospital of Nanjing Medical University, Shan…
  • Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 201620, China.
  • Department of Breast Surgery, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai 200032, China.
  • Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 201620, China. Electronic address: yanbin8988@sjtu.edu.cn.
  • Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 201620, China. Electronic address: xingsun_sjtu@aliyun.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Gu, P., Ding, W., Zhu, W., Shen, L., Zhang, L., Wang, W., Wang, R., Wang, W., Wang, Y., Yan, B., & Sun, X. (2024). MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK/c-Jun and p38 MAPK signaling pathway activation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113191

Vancouver

Gu P, Ding W, Zhu W, Shen L, Zhang L, Wang W, et al. MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK/c-Jun and p38 MAPK signaling pathway activation. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113191

BibTeX
@article{Gu2024,
  author = {Gu, Peng and Ding, Wentao and Zhu, Wenting and Shen, Ling and Zhang, Lei and Wang, Wei and Wang, Ruitao and Wang, Wenhao and Wang, Yanhao and Yan, Bin and Sun, Xing},
  title = {MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK/c-Jun and p38 MAPK signaling pathway activation},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.113191}
}
Kostenlos starten →